Stories about: GlaxoSmithKline

The number of melanoma cases will double over the next 10 years, presenting attractive opportunities for drug companies to improve on existing poor and outdated standards of treatment.

GlaxoSmithKline will see its dominance of the Australian asthma treatment market eroded over the next few years by the arrival of new combination and generic products. That’s according to a new study from industry analysts Datamonitor .

It’s not just the Big Three – CSL,ResMed and Cochlear – with high hopes for 2010. Many other Australian biotechnology companies are either in the final stages of trials and are close to gaining regulatory approval, or they are in the initial stages of commercialising their products, with several forming strategic partnerships to expand into new and lucrative overseas markets.

Datamonitor Group predicts antidiabetics market will continue to expand, but obesity plagued by perception and treatment issues.

Australian researchers close to a breakthrough in cancer treatment using the body's own immune system to destroy cancerous cells.

The Cancer Institute NSW Premier's Award for Outstanding Cancer Researcher

Alchemia’s partner files generic application for fondaparinux

WA company Epichem and the Drugs for Neglected Diseases initiative are collaborating to develop new drugs to treat African sleeping sickness and similar, forgotten diseases.

Nature reports that a peer reviewer leaked an unfavourable report on diabetes drug Avandia to manufacturer.

The annual Research Australia Thank You Day awards have been announced.